ABT-101
HER2 TKI
Programs
ABT-101
ABT-101, is an oral, tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) patients harboring exon 20 insertions (e20i) in HER2, exon20 kinase domain mutation in other solid tumor cancer types, where there’s currently no available treatment for the patients.
ABT-101 demonstrates excellent therapeutic potential and superior safety profile compared to competitors that are under clinical development. It meets challenges of unmet medical needs for cancer drugs targeting HER2 activating mutations (e20i) in HER2.
ABT-301
ABT-301 is a small molecule histone deacetylase inhibitor (HDACi). Cancer cells exhibit higher histone deacetylase activity, which adjusts chromosomal compactness to block the expression of certain tumor suppressor genes. The application of such inhibitors facilitates the expression of tumor suppressor genes, altering the growth, arrest, and differentiation of tumor cells, promoting apoptosis, and ultimately inhibiting tumor growth to achieve cancer treatment.
ABT-301 has demonstrated superior safety in a phase 1 study, opening the door for further clinical development. Data from preclinical studies also indicate that ABT-301 is highly competitive in treating most solid tumors compared to other drugs.
ABT-202
KRAS inhibitors, like other targeted therapies, face the challenge of drug resistance. To address unmet medical needs, Anbogen is developing second-generation KRAS inhibitors to combat resistance mutations. Increasing clinical studies have shown that patients using Sotorasib® and Adagrasib® have developed novel drug resistance mutations, leading to drug resistance.
ABT-202 is a second-generation pan-KRAS inhibitor developed by Anbogens exclusive covalent combination drug design and structural biology design platform.
Pipeline
Programs
Indication
Monotherapy / Combination
Pre-clinical
IND-enabling
Phase 1
Phase 2
Phase 3
Clinical Trial
ABT-101
HER2 TKI
ABT-301
Pan-HDAC Inhibitor
Solid Tumors
Tislelizumab
ABT-202
KRAS Inhibitor
Solid Tumors
Monotherapy
Programs
Programs
ABT-301
Pan-HDAC Inhibitor
Indication
Solid Tumors
Monotherapy / Combination
Tislelizumab
Pipeline
Phase 2
Clinical Trial
Programs
ABT-202
KRAS Inhibitor
Indication
Solid Tumors
Monotherapy / Combination
Monotherapy
Pipeline
Pre-clinical
Clinical Trial
R&D Focus Areas
1
Targets central to well-validated actionable somatic mutations, and epigenetic modification of histone deacetylase inhibition
2
Pursue clinically validated pathways in indications with best-in-class potential
3
Preclinical insights and clinical prove of concept data to drive successful development
4
Anchored in science to transform cancer treatments